Background: Transesophageal echocardiography (TEE) is useful for detecting left atrial (LA) thrombus prior to percutaneous LA catheter ablation in patients with atrial fibrillation (AF). This study was designed to evaluate clinical predictors of LA thrombus and determine indications for TEE screening prior to LA ablation.
eft atrial (LA) catheter ablation is performed as a curative treatment for drug-resistant atrial fibrillation (AF). [1] [2] [3] [4] This technique might have the advantage of a higher success rate for treating persistent AF. 1, 4 However, the LA ablation procedure carries a risk of stroke due to air emboli and/or thrombus formations at the tip of the catheter or sheath in the left atrium. These thromboembolic events occur in 0.9% of cases within 2 weeks of LA ablation. 5, 6 Preexisting LA thrombi might also cause strokes after ablation because the procedures include LA catheter manipulation and possibly also restoration of sinus rhythm. Therefore, the presence of an LA thrombus is a contraindication for LA ablation. 7 
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Transesophageal echocardiography (TEE) provides highquality images of cardiac structure and function. TEE is the most sensitive and specific technique for detecting LA thrombi. 8, 9 However, TEE is an invasive and costly procedure with risk of complications such as trauma, vagal reaction or aspiration due to probe insertion, allergic reactions to topical anesthesia, and hypotension or hypoxia due to conscious sedation.
Pre-ablation TEE is performed to varying degrees by different centers. 6,7, 10 The Heart Rhythm Society (HRS)/European Heart Rhythm Association (EHRA)/European Cardiac Arrhythmia Society (ECAS) Expert Consensus Statement recommends that patients with persistent AF who are in AF at the time of ablation undergo TEE to screen for thrombi regardless of whether they have been anti-coagulated with warfarin prior to ablation. 7 This reflects the lack of consensus as to whether pre-ablation TEE should be routinely performed for patients with paroxysmal AF. Because preprocedural screening with TEE prior to LA ablation is not routinely performed, there are few data on the prevalence and predictors of LA thrombus in this setting. 11 This study was designed to identify clinical predictors of LA thrombus prior to LA ablation and determine appropriate indications for pre-procedural TEE.
Methods

Patient Population
This study included 446 Japanese patients with drug-resistant, paroxysmal or persistent AF (age 59±11 years, 312 males, 136 persistent AF) scheduled to undergo initial LA ablation between January 2005 and September 2008. Paroxysmal AF was defined as recurrent AF (≥2 episodes) that terminates spontaneously within 7 days. Persistent AF was defined as AF sustained beyond 7 days, or lasting less than 7 days but necessitating pharmacological or electrical cardioversion. 6 All patients received TEE screening prior to ablation after written informed consent had been obtained. If the TEE examination detected LA thrombus, ablation was cancelled for that day.
Anticoagulation Protocol
Anticoagulation was performed according to the Japanese Circulation Society (JCS) Guidelines for Pharmacotherapy of Atrial Fibrillation, 12 ie, anticoagulation with warfarin was administered to AF patients with any valvular heart disease and to those with non-valvular heart disease but a history of cardiogenic ischemic stroke, hypertension, congestive heart failure, diabetes mellitus, hypertrophic or dilated cardiomyopathy, or whose age was at least 65 years. The recommended anticoagulation regimen was continued until the day of the ablation procedure. After LA ablation, anticoagulation with warfarin was administered for at least 3 months. Patients with a contraindication for warfarin, or who refused oral anticoagulation, were treated with anti-platelet agents at the discretion of their primary physicians.
CHADS2 Score
The CHADS2 score is a useful scheme for risk stratification of strokes in patients with AF. 13 We calculated CHADS2 scores by adding 1 point each for any of the following -recent congestive heart failure, hypertension, an age of 75 years or older, and diabetes mellitus -and 2 points for a history of stroke or transient ischemic attack. Thus, CHADS2 is an acronym for risk factors, as represented by the CHADS2 score.
Echocardiography
Transthoracic echocardiograms (TTE) were obtained within 48 h before the catheter ablation procedure using Vivid 7 (General Electric, Vingmed Ultrasound, Horten, Norway) with a M3S transducer or Sonos 7500 (Philips Technology, Andover, MA, USA) with a S3 transducer. TTE images were obtained in the standard parasternal long-axis, parasternal short-axis, apical 2-chamber and 4-chamber views with harmonic imaging, pulsed Doppler mitral inflow velocities and tissue Doppler imaging of lateral mitral annulus. Left ventricular end-diastolic and end-systolic dimensions, left ventricular septal and posterior wall thickness, and LA anteroposterior diameter were measured using M-mode echocardiography with a parasternal view. 14 LA superoinferior and mediolateral diameters were obtained in the 4-chamber view at the end-systolic frame preceding mitral valve opening. 14 The LA volume was calculated using the ellipsoid model (LA volume = 4/3 π× (LA anteroposterior diameter/2) (LA superoinferior diameter/2) (LA mediolateral diameter/2). 14 LA diameters and volumes were indexed to the body surface area. Left ventricular diastolic function was estimated as early transmitral inflow velocity/tissue Doppler mitral annular early diastolic velocity (E/E'). 15 TEE was performed in all patients within 24 h before ablation using a Sonos 7500 with a T6210 transducer. Multiple planes of the LA appendage, including a continuous sweep from 0° to 180° were obtained from the mid-esophagus at 5° to 10° increments. LA thrombus was considered to be present if there was a mass that could be distinguished from the surrounding endocardium or pectinate muscles (Figure 1 ). All attending cardiologists performing and interpreting TEE had more than 3 years of post-training and were highly experienced (>50 TEE procedures per year per physician).
Statistical Analysis
Continuous variables were expressed as means ±1 standard deviation and were compared using Student's t-test. Categorical variables were compared using chi-square analysis and Fisher's exact test for small numbers. Because only a limited number of patients had CHADS2 scores ≥2, we combined patients with CHADS2 scores of 2 to 6. Univariate logistic regression was performed to estimate the magnitude of risk associated with potential risk factors for thrombus. Multivariate logistic regression was performed using variables that had significant or borderline significant (P<0.15) associations with the presence of LA thrombus. A value of P<0.05 was considered to indicate a statistically significant difference. (Table 1) TEE examination prior to LA ablation revealed LA thrombus in 13 cases (3.0%), forcing us to cancel the planned ablation (age 67±8 years, 10 males, 12 persistent AF). The thrombus was located in the LA appendage in all 13 patients (Figure 1) . Two patients were in sinus rhythm at the time of TEE. Patient No. 11 had persistent AF, which continued for more than 1 week, and terminated spontaneously 1 day before the planned ablation and TEE examination. Twelve 
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patients had structural heart diseases, which included 6 with non-ischemic cardiomyopathy, 3 with hypertrophic cardiomyopathy, 1 in the dilated phase of hypertensive heart disease, 1 with a posterior myocardial infarction and 1 with moderate aortic stenosis. Only 1 patient did not have structural heart disease.
Anticoagulation was performed in 11 patients (85% 
Thromboembolic Events After LA ablation
After TEE screening, LA ablation was performed in the remaining 433 AF patients without LA thrombus (control group). Three thromboembolic events (0.7%) occurred within 2 weeks after the procedures. Two patients developed subcortical infarctions and the other patient sustained a brain stem infarction. Two patients had CHADS2 score of 2 and the other had CHADS2 score of 0. PT-INR, prothrombin time-international normalized ratio. Other abbreviations see in Table 1 .
YAMASHITA E et al.
Univariate Analysis (Table 2)
Demographic data revealed patients with LA thrombus to be older and have higher prevalences of persistent AF, structural heart disease and history of congestive heart failure than those without LA thrombus. LA thrombus was present in 1.0% (2 LA thrombus cases/199 patients), 3.9% (7 cases/180 patients) and 5.9% (4 cases/67 patients) of patients with CHADS2 scores of 0, 1 and ≥2, respectively, but there were no significant differences among the 3 groups. The frequency of AF at the time of the TEE exam was higher in LA thrombus than in control cases. PT-INR in LA thrombus group was higher than control group (1.92±0.51 vs 1.55±0.55; P<0.05) among the patients receiving warfarin. The echocardiographic data showed that thrombus patients had significantly lower EF, higher LA diameter, LA diameter index, LA volume index, and E/E' than control patients.
Multivariate Analysis (Table 3)
In multiple logistic regression analysis, advanced age (odds ratio (OR) 1.09, 95% confidence interval (CI) 1.0-1.2; P= 0.045), persistent AF (OR 38.1, 95%CI 1.4-988; P=0.028) and structural heart diseases (OR 29.8, 95%CI 2.8-383; P< 0.01) were independent positive predictors of LA thrombus (P<0.05). However, CHADS2 score = 0 (OR 1.7, 95%CI 0.1-19.2; P=0.67) and LA volume index (OR 1.0, 95%CI 0.9-1.1; P=0.96) were not significant predictors of LA thrombus on multivariate analysis. Figure 2 shows the prevalence of LA thrombus in patients without positive predictors. In patients <60 years of age, those with paroxysmal AF and those with lone AF (AF without structural heart diseases), the prevalences of thrombus were 1.8%, 0.32% and 0.27%, respectively. None of the 136 patients with paroxysmal lone AF whose age was below 60 years had LA thrombus prior to ablation.
Discussion
Predictors of LA Thrombus Prior to LA Ablation
We found advanced age, persistent AF and structural heart disease to be predictors of the presence of LA thrombus prior to LA ablation. The prevalence of LA thrombus before ablation in patients <60 years of age with paroxysmal lone AF was also revealed to be extremely low. This observation is consistent with the ACC/AHA/ESC Guidelines, which does not recommend long-term anticoagulation with warfarin for primary prevention of stroke in patients less than 60 years of age with lone AF. 13 It might be reasonable to omit the TEE as a screening examination for LA thrombus in this population as there is little possibility of an increased thromboembolic risk after ablation.
Although CHADS2 scores are useful for stroke risk stratification in AF patients, 13 our study revealed that a CHADS2 score = 0 could not always guarantee the freedom from the thrombus formations prior to ablation without TEE. In the present study, the ages of the 2 thrombus cases with CHADS2 scores = 0 were 63 and 74 years.
Increased size of the left atrium is reportedly often associated with the presence of LA thrombus. 11 However, the present multivariate analysis showed LA size not to be an independent predictor of LA thrombus. Scherr et al demonstrated LA diameter ≥45 mm to be an independent predictor of LA thrombus prior to AF ablation and that the risk of LA thrombus was low in patients with CHADS2 scores of 0 and LA diameters <45 mm. 11 In the current study, there were 2 LA thrombus cases with CHADS2 scores of 0 whose LA diameters were <45 mm. Thus, these 2 criteria were apparently insufficient to exclude LA thrombus.
Severe left ventricular diastolic dysfunction such as amyloidosis or hypertrophic cardiomyopathy could increase the risk for thrombosis in AF patients. 16, 17 Feng et al reported that AF, poor left ventricular diastolic function were independently associated with increased risk for intracardiac thrombosis in patients with amyloidosis. 16 However, we focused on the possibility that E/E', representative parameter of diastolic function, might be one of the predictors of LA thrombus prior to LA ablation, our study revealed that E/E' could not predict LA thrombus in this population.
Clinical Implications
Utilization of TEE prior to AF ablation varies among dif- TEE for LA Thrombus Screening ferent centers performing this procedure. 6,7 In a worldwide survey on catheter ablation for AF, TEE was required before the ablation procedure in 72% of centers. 6 In other centers, TEE may be used selectively or not at all. HRS/EHRA/ECAS guidelines for catheter ablation of AF suggest that patients with persistent AF who are in AF at the time of ablation should be screened with TEE for thrombus. 7 These recommendations are based on expert consensus rather than systematically collected clinical data. However, rhythm at the time of TEE was not a statistically significant predictor of LA thrombus in our study. Two of our patients in sinus rhythm had LA thrombus prior to LA ablation. Frequent AF attacks might prolong atrial stunning, possibly causing LA thrombus even patients in sinus rhythm at the time of TEE. 18 Among several clinical and echocardiographic parameters, advanced age, persistent AF and structural heart disease predicted LA thrombus prior to LA ablation for AF. Therefore, exclusion of LA thrombus with pre-procedural TEE is especially important in patients with advanced age, persistent AF and structural heart diseases. However, the risk of LA thrombus is very low in patients less than 60 years of age with lone paroxysmal AF. If TEE had not been performed in such patients, ie, those less than 60 years of age with lone paroxysmal AF, the utilization of this procedure in our facility would have been reduced by 30% (136 cases) without missing any LA thrombus. Had we not performed TEE in patients with paroxysmal AF or lone AF, we would have reduced utilization by 70% (310 cases) or 83% (369 cases) while missing one LA thrombus. In contrast, had we not performed TEE in patients with paroxysmal AF who were in sinus rhythm, we would have reduced TEE use by 61% (270 cases) but missed one patient with LA thrombus.
Anticoagulation Protocol Prior to LA Ablation
Warfarin was administered for anticoagulation according to the JCS Guidelines for Pharmacotherapy of Atrial Fibrillation prior to LA ablation. 12 Japanese populations have a higher risk of cerebral hemorrhage and lower risk of ischemic stroke. 19 Therefore, European anticoagulation guidelines are not consistently applicable to Japanese patients. Low-dose warfarin (INR 1.6-2.6) is recommended for secondary prevention of stroke in patients with non-valvular AF, especially the elderly, for avoidance of major hemorrhagic complications. [20] [21] [22] Although therapeutic INR intensity in elderly patients with lone AF, according to the JCS Guidelines (1.6-2.6), are lower than the ACC/AHA/ESC recommendations (2.0-3.0), our study showed the prevalences of LA thrombus and thromboembolic events after LA ablation in Japan to be similar to those in previous studies in other countries. 5,11
Study Limitations
Our study has some limitations. First, the present study is a single-center experience, which reflects our patient population and their risk for LA thrombus. Thus, selection bias could exist. Second, the incidence of LA thrombus was not particularly high, and the number of patients with LA thrombus was relatively small. Therefore, further data collection by multiple centers is needed. Third, the results of this study do not allow us to dismiss the possibility that TEE is necessary for other reasons such as detection of patent foramen ovale or measurement of pulmonary vein or LA appendage velocities. The presence of a patent foramen ovale makes LA ablation procedures more difficult. 23 A PFO is positioned anterior and superior compared with the anatomical septum targeted during the transseptal catheterization, resulting in a more anterior-superior access to the LA, which are caused in a less direct approach to the PVs. The consequence of this is less accurate positioning of the catheter and a lack of catheter stability. Furthermore, with a PFO there is a larger septal hole compared with a trans-septal puncture, leading to a lack of reducing catheter stability. 23 Pulmonary vein velocities and LA appendage velocities are important indices for evaluation of LA function. 14 
